BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib

Cancer Genetics and Cytogenetics

Volumn 159, Issue 2, 2005, Pages 164-167

  Gadzicki, Dorothea ^a   Von Neuhoff, Nils ^a   Steinemann, Doris ^a   Just, Marianne ^b   Büsche, Guntram ^a   Kreipe, Hans ^a   Wilkens, Ludwig ^a   Schlegelberger, Brigitte ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Specialist for Hematology and Internal Oncology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; HYDROXYUREA; IMATINIB;

AGED; ARTICLE; CASE REPORT; CELL DIFFERENTIATION; CELL POPULATION; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; INTERPHASE; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

AGED; ANTINEOPLASTIC AGENTS; CHROMOSOME ABERRATIONS; DRUG RESISTANCE, NEOPLASM; FEMALE; FUSION PROTEINS, BCR-ABL; GENE AMPLIFICATION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KARYOTYPING; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; PYRIMIDINES; TRANSLOCATION, GENETIC;

EID: 19344364557     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2004.09.021     Document Type: Article

References (15)

1. B.J. Druker, M. Talpaz, D.J. Rasta, B. Peng, E. Buchdunger, J.M. Ford, N.B. Lydon, H. Kantarjian, R. Capdeville, S. Ohno-Jones, and C.L. Sawyers Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med 344 2001 1031 1037
2. M. Talpaz, R.T. Silver, B.J. Druker, J.M. Goldman, C. Gambacorti-Passerini, F. Guilhot, C.A. Schiffer, T. Fischer, M.W.N. Deininger, A.L. Lennard, A. Hochhaus, O.G. Ottmann, A. Gratwohl, M. Baccarani, R. Stone, S. Tura, F.X. Mahon, S. Fernandes-Reese, I. Gathmann, R. Capdeville, H.M. Kantarjian, and C.L. Sawyers Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study Blood 99 2002 1928 1937
3. C.B. Gambacorti-Passerini, R.H. Gunby, R. Piazza, A. Galietta, R. Rostagno, and L. Scapozza Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias Lancet Oncol 4 2003 75 85
4. A. Hochhaus, S. Kreil, A.S. Corbin, P. La Rosée, M.C. Müller, T. Lahaye, B. Hanfstein, C. Schoch, N.C.P. Cross, U. Berger, H. Gschaidmeier, B.J. Druker, and R. Hehlmann Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy Leukemia 16 2002 2190 2196
5. B. Schlegelberger, S. Metzke, S. Harder, R. Zühlke-Jenisch, Y. Zhang, and R. Siebert Classical and molecular cytogenetics of tumor cells R.-D. Wegner Diagnostic cytogenetics 1999 Springer-Verlag New York, Berlin, Heidelberg 151 185
6. ISCN 1995: an international system for human cytogenetic nomenclature (1995) F. Mitelman 1995 S. Karger Basel
7. C.B. Lozzio, and B.B. Lozzio Cytotoxicity of a factor isolated from human spleen J Natl Cancer Inst 50 1973 535 538
8. C. Roche-Lestienne, V. Soenen-Cornu, N. Grardel-Duflos, J.-L. Laï, N. Philippe, T. Facon, P. Fenaux, and C. Preudhomme Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment Blood 100 2002 1014 1018
9. A. Gaiger, T. Henn, E. Hörth, K. Geissler, G. Mitterbauer, T. Maier-Dobersberger, H. Greinix, C. Mannhalter, O.A. Haas, and K. Lechner Increase of BCR-ABL chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression Blood 86 1995 2371 2378
10. P. Le Coutre, E. Tassi, M. Varella-Garcia, R. Barni, L. Mologni, G. Cabrita, E. Marchesi, R. Supino, and C. Gambacorti-Passerini Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification Blood 95 2000 1758 1766
11. M.E. Gorre, M. Mohammed, K. Ellwood, N. Hsu, R. Paquette, P.N. Rao, and C.L. Sawyers Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification Science 293 2001 876 880
12. A. Hochhaus Cytogenetic and molecular mechanisms of resistance to imatinib Semin Hematol 40 2 Suppl 2 2003 69 79
13. S. Metzke-Heidemann, L. Harder, S. Gesk, R. Schoch, S. Jenisch, W. Grote, R. Siebert, and B. Schlegelberger Integration of amplified BCR/ABL fusion genes into the short arm of chromosome 17 as a novel mechanism of disease progression in chronic myeloid leukemia Genes Chromosomes Cancer 31 2001 10 14
14. L.J. Campbell, C. Patsouris, K.C. Rayeroux, K. Somana, E.H. Januszewicz, and J. Szer BCR-ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration Cancer Genet Cytogenet 139 2002 30 33
15. F. Morel, M.-J. Le Bris, A. Herry, G. Le Calvez, V. Marion, J.-F. Abgrall, C. Berthou, and M. De Braekeleer Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib Eur J Haematol 70 2003 235 239